A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)

Recruiting

Phase 2

SatralizumabA Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)

Sponsor:

Hoffmann-La Roche

Code:

NCT06450639

Conditions

Duchenne Muscular Dystrophy

Eligibility Criteria

Sex: Male

Age: 8 - 17

Healthy Volunteers: Not accepted

Interventions

Satralizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2025-04-08.